Thyroid Eye Disease Program News Today

-- Data at Week 24 show 2.41 mm reduction in proptosis in patients treated with TEPEZZA compared with 0.92 mm in those who received placebo; 62% of TEPEZZA patients had clinically meaningful... | June 17, 2023

According to Horizon Therapeutics, the updated indication language reinforces the importance of access for patients across the full spectrum of TED activity or duration.

-- At Week 24, patients treated with TEPEZZA achieved a 2.41 mm reduction in proptosis from baseline compared with 0.92 mm for those receiving placebo -- -- 62% of patients treated with TEPEZZA had... | April 10, 2023

Announced today by Horizon Therapeutics, the positive and statistically significant data supports the efficacy of teprotumumab across a spectrum of patients with TED regardless of disease activity or duration.

Teprotumumab, a minimally invasive insulin-like growth factor I blocking antibody, has been shown to enhance symptoms, appearance, and quality of life in patients with thyroid eye disease, according to a study.

Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their

- Clinical and in vitro data presented in three late-breaking presentations at ATA provide emerging evidence of VRDN-001 efficacy and differentiation

An anti-IGF-1R antibody VRDN-001developed by Viridian Therapeutics has succeeded in a phase I/II clinical trial of people with active thyroid eye disease, with participants seeing an average 2.4 mm...

Patients with active thyroid eye disease (TED) could benefit from rapid, significant improvements after positive data emerged from a trial.

Are your eyes dry, uncomfortable, and bulging? You could have thyroid eye disease, especially if you already have Graves’ disease. Learn more about TED.